Mogamulizumab is a defucosylated IgG1 kappa monoclonal antibody that depletes CCR4-expressing cells through potent ADCC for the treatment of CTCL. This evidence concerns the gene CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma.